Compare DTCK & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DTCK | NVNO |
|---|---|---|
| Founded | 1999 | 1987 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 7.3M |
| IPO Year | 2023 | N/A |
| Metric | DTCK | NVNO |
|---|---|---|
| Price | $0.29 | $11.69 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 9.0M | 23.0K |
| Earning Date | 12-23-2025 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $160,529,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.43 | N/A |
| 52 Week Low | $0.23 | $9.81 |
| 52 Week High | $6.89 | $196.70 |
| Indicator | DTCK | NVNO |
|---|---|---|
| Relative Strength Index (RSI) | 41.71 | 93.18 |
| Support Level | $0.30 | $9.81 |
| Resistance Level | $0.33 | $12.79 |
| Average True Range (ATR) | 0.03 | 0.51 |
| MACD | 0.02 | 1.36 |
| Stochastic Oscillator | 3.33 | 92.91 |
Davis Commodities Ltd is an agricultural commodity trading company based in Singapore, which specializes in the trading of three main categories of agricultural commodities, namely sugar, rice, and oil and fat products. It distributes agricultural commodities to various markets, including Asia, Africa, and the Middle East. The company also provides customers of commodity offerings with complementary, ancillary services such as warehouse handling and storage, and logistics services. The Company operates across four main segments: the sale of sugar, rice, oil, and fat products, and others. Among these, the sale of sugar stands out as the primary revenue generator, contributing significantly to the company's overall income.
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.